{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-004104","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.851268+00:00","generated_at":"2026-06-19T01:26:57.458960+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Plus Therapeutics reports FY2022 net loss $20.3M; cash $18.1M; CPRIT grant $17.6M","bullets":["Net loss $20.3M ($0.77/share) vs $13.4M ($1.11/share) in FY2021; operating expenses $19.9M.","Cash $18.1M at Dec 31, 2022; with grants and capital sources, expects funding through 2025.","Awarded $17.6M CPRIT grant for rhenium obisbemeda leptomeningeal metastases trial.","Enrolled first patient in ReSPECT-GBM Phase 2b; completed second cohort in ReSPECT-LM Phase 1.","Grant revenue $224k from CPRIT; received first ~$1.9M in Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-004104","json":"https://secwatch.observer/filing/0000950170-23-004104.json","markdown":"https://secwatch.observer/filing/0000950170-23-004104.md","text":"https://secwatch.observer/filing/0000950170-23-004104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023004104/0000950170-23-004104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023004104/pstv-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T01:26:57.458960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ea31b7a0f194c36bf4264e9b79ae231dfdaaedc","claim":"PLUS THERAPEUTICS, INC. reported the fourth quarter and year ended December 31, 2022 results: net income $20.3 million, EPS $(0.77) per share.","evidence_excerpt":"Net loss for full year 2022 was $20.3 million, or $(0.77) per share, compared to a net loss of $13.4 million, or $(1.11) per share, for full year 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000095017023004104/0000950170-23-004104-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Net income","value":"$20.3 million"},{"label":"EPS","value":"$(0.77) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}